The Disability Rights Critique of Technologies that Eliminate Human Genetic Variation
By Rosemarie Garland-Thomson,
ELSIhub
| 04. 12. 2023
Photo by Kimberly Farmer on Unsplash
Introduction
The development and use of an expanding range of medical technologies that yield genetic information about embryos and fetuses has raised ethical questions about whether and how this increasingly routine set of practices discriminates against people with disabilities. A conversation in the form of academic articles and public media offers explications and critiques about the social and moral harms human gene editing and prenatal genetic testing and the selective reproduction practices it prompts bring to humanity. These purported harms range from increased social inequity—at the very least—to structural and individual violence—at the very most.
This collection suggests that conversations about these technologies have changed over time and also reflects the varied communities engaged in those conversations over time and across social locations. The collection thus focuses on the health humanities in the broadest sense. This means that the data, evidence, and knowledge it gathers come from the lives of individuals, families, and human communities who live with disabilities and illnesses, not from medical-scientific or clinical data. The stories in the final section of...
Related Articles
By Abby McCloskey, The Dallas Morning News | 10.10.2025
We Texans like to do things our way — leave some hide on the fence rather than stay corralled, as goes a line in Wallace O. Chariton’s Texas dictionary This Dog’ll Hunt. Lately, I’ve been wondering what this ethos...
By Jay S. Kaufman, Los Angeles Review of Books | 09.27.2025
This is the 10th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring the history of eugenics and the ways it shapes our present. The series is organized by Osagie K. Obasogie in...
By Julia Black, MIT Technology Review | 10.16.2025
Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of...
By Meagan Parrish, PharmaVoice | 10.10.2025
When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off...